気管支拡張症治療薬市場：薬剤クラス別、投与経路別、エンドユーザー別-2025-2030年の世界予測

気管支拡張症治療薬市場は、2023年に13億9,000万米ドルと評価され、2024年には15億米ドルに達すると予測され、CAGR 9.86％で成長し、2030年には27億米ドルに達すると予測されています。

気管支拡張症治療薬市場は、気管支拡張症（肺の気道の一部が永続的に拡大することを特徴とする疾患）の治療を目的とする医薬品の特定分野を網羅しています。この市場には、抗生物質、去痰薬、コルチコステロイド、気管支拡張薬などが含まれ、慢性症状の管理や疾患の進行防止に不可欠です。これらの薬剤の必要性は、呼吸器疾患の有病率の上昇、人口の高齢化、気管支拡張症に対する認識と診断の増加によってもたらされています。主な用途は、肺機能の改善、増悪の抑制、気管支拡張症に関連する細菌感染の管理を目的とした臨床療法です。主なエンドユーザーは病院、在宅医療、専門クリニック、研究機関であり、多様な消費者層が存在します。成長要因としては、医薬品開発の進歩、医療費の増加、個別化医療の重視などが挙げられます。新たなビジネスチャンスは、生物学的製剤や遺伝子治療などの新規治療法の開発にあります。企業は研究開発に投資し、研究機関と戦略的提携を結ぶことで、これらを活用することができます。しかし、高い治療費、新興国市場での認知度の低さ、複雑な規制当局の承認といった要因によって、市場の成長は阻まれています。また、ジェネリック医薬品との競合も制約となっています。吸入可能な製剤など、より優れたデリバリー・メカニズムを持つドラッグの開発や、疾患の早期発見のためのバイオマーカーのさらなる研究開発には、イノベーションの可能性が存在します。市場はダイナミックで、絶え間ない製品革新と規制の変更を特徴としており、企業は機敏さと先見性を維持する必要があります。成長を目指す企業は、新たな市場機会を効果的に活用するため、技術の進歩や新たな治療技術に後れを取らないようにしなければならないです。強固なサプライチェーンマネジメント、高度な提携、多様な患者ニーズに対応する製品を含むポートフォリオの多様化は、競争力を獲得する上で極めて重要です。

市場力学：急速に進化する気管支拡張症治療薬市場の主要市場インサイトを公開

気管支拡張症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 呼吸器感染症および呼吸器疾患の増加
  • 呼吸器の健康に対する意識を高めるための政府の取り組み
  • 短時間作用型および長時間作用型気管支拡張症治療薬の参入
• 市場抑制要因
  • 一般的な気管支拡張症治療薬に対する病原体の耐性
• 市場機会
  • 吸入抗生物質や先進気管支拡張薬の開発につながる技術革新
  • 気管支拡張症治療薬開発のための研究開発活動と臨床試験
• 市場の課題
  • 気管支拡張症治療薬の安全性と有効性に関する規制上の懸念

ポーターのファイブフォース気管支拡張症治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、気管支拡張症治療薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：気管支拡張症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、気管支拡張症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析気管支拡張症治療薬市場における競合情勢の把握

気管支拡張症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス気管支拡張症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、気管支拡張症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨気管支拡張症治療薬市場における成功への道筋を描く

気管支拡張症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 呼吸器感染症および疾患の増加
    • 呼吸器の健康に関する意識を高める政府の取り組み
    • 短時間作用型と長時間作用型の気管支拡張症治療薬のエントリー
  • 抑制要因
    • 一般的な病原菌に対する耐性気管支拡張症治療薬
  • 機会
    • 吸入抗生物質と先進的な気管支拡張剤の開発につながるイノベーション
    • 研究開発活動と臨床試験気管支拡張症治療薬
  • 課題
    • 気管支拡張症治療薬の安全性と有効性に関する規制上の懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 気管支拡張症治療薬市場薬剤クラス別

• 抗炎症剤
• 抗生物質
• 気管支拡張薬
• 粘液溶解薬

第7章 気管支拡張症治療薬市場：投与経路別

• 吸入
• 静脈内
• オーラル

第8章 気管支拡張症治療薬市場：エンドユーザー別

• クリニック
• 病院
• 調査機関

第9章 南北アメリカの気管支拡張症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の気管支拡張症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの気管支拡張症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AdvaCare Pharma
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Cipla Limited
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Limited
• Lupin Limited
• Mylan Inc. by Viatris Inc.
• Nephron Pharmaceuticals Corporation
• Novartis AG
• Perrigo Company PLC
• Pfizer Inc.
• Prasco Laboratories
• Ralington Pharma LLP
• Steris Healthcare Pvt. Ltd.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
• Zydus Group

LIST OF FIGURES

• FIGURE 1. BRONCHIECTASIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. BRONCHIECTASIS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BRONCHIECTASIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BRONCHIECTASIS DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 30. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 47. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 50. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 102. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 114. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 117. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 147. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Bronchiectasis Drugs Market was valued at USD 1.39 billion in 2023, expected to reach USD 1.50 billion in 2024, and is projected to grow at a CAGR of 9.86%, to USD 2.70 billion by 2030.

The bronchiectasis drugs market encompasses a specific sector of pharmaceuticals aimed at treating bronchiectasis, a condition characterized by permanent enlargement of parts of the airways in the lungs. This market's scope includes antibiotics, expectorants, corticosteroids, and bronchodilators, essential in managing chronic symptoms and preventing disease progression. The necessity for these drugs is driven by the rising prevalence of respiratory diseases, aging populations, and increasing awareness and diagnosis of bronchiectasis. Applications primarily revolve around clinical therapies to improve lung function, reduce exacerbations, and manage bacterial infections associated with the condition. Key end-users are hospitals, homecare, specialty clinics, and research institutions, highlighting a diverse consumer base. Influencing growth factors include advancements in drug development, increasing healthcare expenditure, and a stronger emphasis on personalized medicine. Emerging opportunities lie in the development of novel therapies, such as biologics and gene therapy, which promise targeted treatments with improved efficacy. Companies can capitalize on these by investing in R&D and forming strategic alliances with research institutes. However, market growth is challenged by factors such as high treatment costs, limited awareness in developing regions, and complex regulatory approvals. Competition from generic drugs also presents a limitation. Innovation potential exists in developing drugs with better delivery mechanisms, such as inhalable formulations, and conducting further research into biomarkers for early disease detection. The market is dynamic, characterized by constant product innovation and regulatory changes, requiring businesses to maintain agility and foresight. Companies seeking growth should stay abreast of technological advancements and emerging therapeutic techniques to harness new market opportunities effectively. Robust supply chain management, advanced collaborations, and diversification of portfolios to include products addressing varied patient needs will be crucial in gaining a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchiectasis Drugs Market

The Bronchiectasis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of respiratory tract infections and diseases
  • Government initiatives to raise awareness about respiratory health
  • Entry of short-acting and long-acting bronchiectasis drugs
• Market Restraints
  • Resistance of pathogenic species to common bronchiectasis drugs
• Market Opportunities
  • Innovations leading to the development of inhaled antibiotics and advanced bronchodilators
  • R&D activities and clinical trials to develop bronchiectasis drugs
• Market Challenges
  • Regulatory concerns about the safety and efficacy of bronchiectasis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Bronchiectasis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchiectasis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchiectasis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchiectasis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchiectasis Drugs Market

A detailed market share analysis in the Bronchiectasis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchiectasis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchiectasis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchiectasis Drugs Market

A strategic analysis of the Bronchiectasis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchiectasis Drugs Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Bronchiectasis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Anti-inflammatory Agents, Antibiotics, Bronchodilators, and Mucolytics.
• Based on Route of Administration, market is studied across Inhalation, Intravenous, and Oral.
• Based on End-Users, market is studied across Clinic, Hospital, and Research Institute.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of respiratory tract infections and diseases
    • 5.1.1.2. Government initiatives to raise awareness about respiratory health
    • 5.1.1.3. Entry of short-acting and long-acting bronchiectasis drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Resistance of pathogenic species to common bronchiectasis drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovations leading to the development of inhaled antibiotics and advanced bronchodilators
    • 5.1.3.2. R&D activities and clinical trials to develop bronchiectasis drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory concerns about the safety and efficacy of bronchiectasis drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bronchiectasis Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Anti-inflammatory Agents
• 6.3. Antibiotics
• 6.4. Bronchodilators
• 6.5. Mucolytics

7. Bronchiectasis Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Inhalation
• 7.3. Intravenous
• 7.4. Oral

8. Bronchiectasis Drugs Market, by End-Users

• 8.1. Introduction
• 8.2. Clinic
• 8.3. Hospital
• 8.4. Research Institute

9. Americas Bronchiectasis Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bronchiectasis Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bronchiectasis Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AdvaCare Pharma
• 2. AstraZeneca PLC
• 3. Boehringer Ingelheim International GmbH
• 4. Cipla Limited
• 5. GlaxoSmithKline PLC
• 6. Glenmark Pharmaceuticals Limited
• 7. Lupin Limited
• 8. Mylan Inc. by Viatris Inc.
• 9. Nephron Pharmaceuticals Corporation
• 10. Novartis AG
• 11. Perrigo Company PLC
• 12. Pfizer Inc.
• 13. Prasco Laboratories
• 14. Ralington Pharma LLP
• 15. Steris Healthcare Pvt. Ltd.
• 16. Sun Pharmaceutical Industries Limited
• 17. Teva Pharmaceutical Industries Ltd.
• 18. Zydus Group